Determining which of these inhibitors is most effective for patients with NSCLC and other cancers with KRAS G12C mutations, and whether combining these inhibitors with other drugs leads to better treatment outcomes, are key emerging questions. This evidence concerns the gene KRAS and non-small cell lung carcinoma.